Kevin M. Lalande, Director at LUMOS PHARMA, INC. (LUMO), bought 130,708 shares at $8.73 ($1.2M) on 2021-08-20, disclosed to the SEC on 2021-08-24.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.73 | 35,679 | $311K | 26.2% |
| 2 | $8.73 | 35,679 | $311K | 26.2% |
| 3 | $9.58 | 37,800 | $362K | 30.5% |
| 4 | $9.45 | 10,775 | $102K | 8.6% |
| 5 | $9.45 | 10,775 | $102K | 8.6% |
| Total | $9.09 avg | 130,708 |
| $1.2M |
| 100% |
| Filing → |
| LUMO | BUY | 2021-09-07 | $274K | — | Filing → |
| LUMO | BUY | 2021-09-01 | $269K | — | Filing → |
| LUMO | BUY | 2021-08-27 | $314K | — | Filing → |